Biotechnology advances: Currently, there are over 70 licensed vaccines, which prevent the
pathogenesis of around 30 viruses and bacteria. Nevertheless, there are
still important challenges in this area, which include the development
of more active, non-invasive, and thermo-resistant vaccines. Important
biotechnological advances have led to safer subunit antigens, such as
proteins, peptides, and nucleic acids. However, their limited
immunogenicity has demanded potent adjuvants that can strengthen the
immune response. Particulate nanocarriers hold a high potential as
adjuvants in vaccination. Due to their pathogen-like size and structure,
they can enhance immune responses by mimicking the natural infection
process.
Additionally, they can be tailored for non-invasive mucosal
administration (needle-free vaccination), and control the delivery of
the associated antigens to a specific location and for prolonged times,
opening room for single-dose vaccination. Moreover, they allow
co-association of immunostimulatory molecules to improve the overall
adjuvant capacity. The natural and ubiquitous character of
polysaccharides, together with their intrinsic immunomodulating
properties, their biocompatibility, and biodegradability, justify their
interest in the engineering of nanovaccines. In this review, we aim to
provide an overview of the state-of-the-art regarding the application of
nanotechnology
in vaccine delivery, with a focus on the most recent advances in the
development and application of polysaccharide-based antigen
nanocarriers.